Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience - Summary - MDSpire

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

  • By

  • Fabian J. K. Allmendinger

  • Maximilian Deng

  • Sebastian Regnery

  • Lars Wessel

  • Katharina Kozyra

  • Felix Englert

  • Ricarda Wickert

  • Jannik Walter

  • Lucas Mose

  • Thomas Tessonnier

  • Sandro M. Krieg

  • Jürgen Debus

  • Laila König

  • Tanja Adena-Eichkorn

  • June 12, 2026

  • 0 min

Share

Objective:

To report long-term institutional experience of adjuvant proton radiotherapy (PRT) in patients with complex residual pituitary adenomas (PAs).

Approach:
    Key Findings:
    • PRT offers a dosimetric advantage over conventional radiotherapy.
    • Insights into the criteria for selecting patients for adjuvant PRT were observed.
    Interpretation:

    Omit this section or rephrase to reflect only the findings presented.

    Limitations:
    • Retrospective design may introduce bias.
    • Limited sample size of 22 patients.
    Conclusion:

    This study reports on the long-term effects and decision-making processes regarding adjuvant PRT for residual PAs.

Original Source(s)

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

  • by Fabian J. K. Allmendinger, Maximilian Deng, Sebastian Regnery, Lars Wessel, Katharina Kozyra, Felix Englert, Ricarda Wickert, Jannik Walter, Lucas Mose, Thomas Tessonnier, Sandro M. Krieg, Jürgen Debus, Laila König, Tanja Adena-Eichkorn

  • June 12, 2026

Related Content

Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma

Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer